Tyra Biosciences Inc
TYRA10.405USD
+0.035+0.34%
交易中 （美東）報價延遲15分鐘
552.40M總市值
虧損本益比TTM
關於 Tyra Biosciences Inc 公司
Tyra Biosciences, Inc. 是一家臨牀階段的生物技術公司。該公司專注於開發針對成纖維細胞生長因子受體 (FGFR) 生物學領域的巨大機遇的精準藥物。其內部精準醫療平臺 SNAP 通過迭代分子 SNAPshot 實現快速而精準的藥物設計，有助於預測導致對現有療法產生獲得性耐藥性的基因變異。該公司最初的重點是應用其加速小分子藥物發現引擎來開發針對腫瘤和基因定義疾病的療法。其主要候選產品 TYRA-300 是一種在研的口服 FGFR3 選擇性抑制劑，正在國際、多中心、開放標籤 1 期臨牀研究 SURF301 中進行評估。其第二個腫瘤候選產品 TYRA-200 是一種在研的口服 FGFR1/2/3 抑制劑，具有抗激活 FGFR2 基因變異以及臨牀上重要的分子制動和守門人耐藥突變的功效。
公司簡介
公司代碼TYRA
公司名稱Tyra Biosciences Inc
上市日期Sep 15, 2021
CEODr. Todd James Harris, Ph.D.
員工數量60
證券類型Ordinary Share
年結日Sep 15
公司地址2656 State Street
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92008
電話16197284760
網址https://tyra.bio/
公司代碼TYRA
上市日期Sep 15, 2021
CEODr. Todd James Harris, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rehan Verjee
Mr. Rehan Verjee
Independent Director
Independent Director
--
--
Dr. S. Michael Rothenberg, M.D., Ph.D.
Dr. S. Michael Rothenberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas (Doug) Warner, M.D.
Dr. Douglas (Doug) Warner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy Conrad
Ms. Amy Conrad
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月11日 週三
更新時間: 6月11日 週三
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
22.94%
Alta Partners
7.67%
Nextech Invest, Ltd.
7.63%
BVF Partners L.P.
7.42%
Canaan Partners
6.79%
Other
47.56%
持股股東
持股股東
佔比
RA Capital Management, LP
22.94%
Alta Partners
7.67%
Nextech Invest, Ltd.
7.63%
BVF Partners L.P.
7.42%
Canaan Partners
6.79%
Other
47.56%
股東類型
持股股東
佔比
Venture Capital
39.16%
Investment Advisor
23.43%
Hedge Fund
23.32%
Investment Advisor/Hedge Fund
15.94%
Individual Investor
3.49%
Private Equity
3.30%
Research Firm
0.89%
Pension Fund
0.27%
Bank and Trust
0.12%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
236
58.55M
110.09%
+1.18M
2025Q1
239
56.06M
105.46%
-647.87K
2024Q4
219
50.96M
100.70%
-3.70M
2024Q3
195
53.66M
101.74%
-3.04M
2024Q2
179
53.85M
102.74%
-1.82M
2024Q1
167
53.85M
102.76%
+5.34M
2023Q4
151
42.86M
99.62%
-3.01M
2023Q3
152
44.80M
104.35%
-3.44M
2023Q2
147
44.53M
104.65%
-3.27M
2023Q1
133
44.06M
103.88%
+915.22K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
12.20M
22.94%
+1.56M
+14.68%
Jun 16, 2025
Alta Partners
4.08M
7.67%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
4.06M
7.63%
--
--
Mar 31, 2025
BVF Partners L.P.
3.94M
7.42%
--
--
Mar 31, 2025
Canaan Partners
4.14M
7.79%
-35.27K
-0.84%
Mar 31, 2025
TCG Crossover Management, LLC
2.90M
5.45%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.88M
5.42%
+1.89M
+190.89%
Mar 31, 2025
Commodore Capital LP
2.75M
5.17%
+1.80M
+189.47%
May 07, 2025
Janus Henderson Investors
2.69M
5.06%
+946.92K
+54.22%
Mar 31, 2025
Kynam Capital Management LP
2.41M
4.52%
+1.88M
+353.57%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
ALPS Medical Breakthroughs ETF
0.34%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
JPMorgan Fundamental Data Science Small Core ETF
0.05%
iShares Micro-Cap ETF
0.05%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.83%
ALPS Medical Breakthroughs ETF
佔比0.34%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.05%
iShares Micro-Cap ETF
佔比0.05%
iShares Biotechnology ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Schwab U.S. Small-Cap ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
